Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 A Large Therapy Area with Varying Unmet Needs across Indications 5
2.2 A Large Pipeline with a High Degree of First-in-Class Innovation 5
3 The Case for Innovation in the Oncology Market 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 9
3.6 Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Therapy Area Overview 10
4.1.1 Epidemiology 10
4.1.2 Etiology 14
4.1.3 Pathophysiology 16
4.1.4 Diagnosis 22
4.1.5 Prognosis and Disease Staging 23
4.2 Treatment Options 25
4.2.1 Surgery 25
4.2.2 Radiation Therapy 26
4.2.3 Chemotherapy 27
4.2.4 Hormonal Therapies 28
4.2.5 Targeted Therapies 29
4.2.6 Immunotherapies 30
4.3 Overview of Marketed Products within Cancer Immunotherapy 32
4.4 Current Unmet Needs across the Oncology Markets 34
5 Assessment of Pipeline Product Innovation 36
5.1 Cancer Immunotherapies Pipeline by Phase, Molecule Type and Molecular Target 36
5.2 Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family 40
5.3 First-in-Class Pipeline Programs 40
5.3.1 First-in-Class Cancer Immunotherapy Products by Phase, Molecule Type and Molecular Target 42
6 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 79
6.1 The Complexity of Signaling Networks in Oncology 79
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 79
6.3 First-in-Class Target Matrix Assessment 79
7 First-in-Class Target Assessment 84
7.1 Pipeline Programs that Target XXX 84
7.2 Pipeline Programs that Target XXX 85
7.3 Pipeline Programs that Target XXX 87
7.4 Pipeline Programs that Target XXX 88
7.5 Pipeline Programs that Target XXX 89
7.6 Pipeline Programs that Target XXX 92
7.7 Pipeline Programs that Target XXX 93
7.8 Pipeline Programs that Target XXX 95
7.9 Pipeline Programs that Target XXX 96
7.10 Conclusion 98
8 Deals and Strategic Consolidations 99
8.1 Licensing Deals 99
8.2 Co-development Deals 105
9 Appendix 121
9.1 Abbreviations 121
9.2 References 122
9.3 Research Methodology 133
9.3.1 Data Integrity 133
9.3.2 Innovative and Meaningful Analytical Technique and Frameworks 134
9.3.3 Evidence-based Analysis and Insight 134
9.4 Secondary Research 134
9.4.1 Market Analysis 134
9.4.2 Pipeline Analysis 134
9.4.3 First-in-Class Matrix Assessment 134
9.4.4 First-in-Class Target Profiles 135
9.4.5 Licensing and Co-Development Deals 135
9.5 Contact Us 135
9.6 Disclaimer 135